s 12024 has been researched along with Alzheimer Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allain, H; Gandon, JM; Guez, D; Malbezin, M; Neuman, E; Salzman, V; Wesnes, K | 1 |
| Amouyel, P; Guez, D; Helbecque, N; Levy, R; Neuman, E; Richard, F | 1 |
| Jochemsen, R; Lachaud-Pettiti, V; Laveille, C; Neuman, E | 1 |
| Derouesné, C; Guez, D; Missonnier, P; Ragot, R; Renault, B | 1 |
1 review(s) available for s 12024 and Alzheimer Disease
| Article | Year |
|---|---|
Application of population pharmacokinetics to the phase II development of an anti-Alzheimer's disease compound, S12024.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Bayes Theorem; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Middle Aged; Models, Statistical; Morpholines; Quinolines; Randomized Controlled Trials as Topic | 1998 |
3 trial(s) available for s 12024 and Alzheimer Disease
| Article | Year |
|---|---|
Bridging study of S12024 in 53 in-patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Morpholines; Psychomotor Performance; Quinolines; Random Allocation | 1997 |
APOE genotyping and response to drug treatment in Alzheimer's disease.
Topics: Alzheimer Disease; Apolipoproteins E; Genotype; Humans; Mental Status Schedule; Morpholines; Quinolines | 1997 |
Automatic attentional shifts induced by a noradrenergic drug in Alzheimer's disease: evidence from evoked potentials.
Topics: Adrenergic Agents; Aged; Alzheimer Disease; Attention; Cerebral Cortex; Cognition Disorders; Cross-Over Studies; Discrimination, Psychological; Double-Blind Method; Event-Related Potentials, P300; Evoked Potentials; Female; Humans; Male; Middle Aged; Morpholines; Multivariate Analysis; Nootropic Agents; Norepinephrine; Perceptual Masking; Quinolines; Volition | 1999 |